(CGEM) Cullinan Oncology - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US2300311063

Cancer Therapies, Autoimmune Disease Treatments, Monoclonal Antibodies, Small Molecules, Bispecific Antibodies

CGEM EPS (Earnings per Share)

EPS (Earnings per Share) of CGEM over the last years for every Quarter: "2020-03": -0.26, "2020-06": -0.45, "2020-09": -0.26, "2020-12": -0.68, "2021-03": -0, "2021-06": -0.36, "2021-09": -0.4, "2021-12": -0.74, "2022-03": -0.27, "2022-06": 3.77, "2022-09": -0.54, "2022-12": -0.59, "2023-03": -1.42, "2023-06": -0.81, "2023-09": -0.92, "2023-12": -0.56, "2024-03": -0.86, "2024-06": -0.76, "2024-09": -0.7, "2024-12": -0.81, "2025-03": -0.82,

CGEM Revenue

Revenue of CGEM over the last years for every Quarter: 2020-03: 0, 2020-06: 0, 2020-09: 0, 2020-12: 0, 2021-03: 18.943, 2021-06: 0, 2021-09: 0, 2021-12: -37.848114, 2022-03: 0, 2022-06: 0, 2022-09: 0, 2022-12: 0, 2023-03: 0, 2023-06: 0, 2023-09: 0, 2023-12: 0, 2024-03: 0, 2024-06: 0, 2024-09: 0, 2024-12: 0, 2025-03: 0,

Description: CGEM Cullinan Oncology

Cullinan Therapeutics, Inc. (NASDAQ:CGEM) is a clinical-stage biopharmaceutical company focused on developing therapies for autoimmune diseases and cancer. The companys pipeline includes several promising candidates, such as zipalertinib, a small molecule in Phase 3 trial for non-small cell lung cancer, and CLN-978, a T cell engager for treating systemic lupus erythematosus and rheumatoid arthritis.

From a clinical perspective, the progress of zipalertinib in Phase 3 trials is significant, as it indicates a potential breakthrough in treating non-small cell lung cancer. Additionally, CLN-978s potential in treating autoimmune diseases like systemic lupus erythematosus and rheumatoid arthritis could provide a new therapeutic option for patients. Key Performance Indicators (KPIs) to watch include the trial completion rates, patient response rates, and potential FDA approval timelines.

From a financial perspective, Cullinan Therapeutics has a market capitalization of $462.68M USD, with a forward P/E ratio of 6.30, indicating a relatively low valuation compared to its projected earnings. The companys return on equity (RoE) is -29.47, suggesting significant investment in research and development. KPIs to monitor include the companys cash burn rate, R&D expenses as a percentage of revenue, and potential milestone payments from partnerships.

The companys collaborations with Adimab, LLC and Taiho Pharmaceutical Co., Ltd are also noteworthy, as they provide access to new technologies and potential co-development opportunities. Key metrics to track include the progress of these collaborations, potential milestone payments, and the impact on the companys cash reserves.

Overall, Cullinan Therapeutics promising pipeline, collaborations, and relatively low valuation make it an interesting opportunity for investors. However, the high-risk nature of biopharmaceutical investments and the companys negative RoE require careful consideration of the potential risks and rewards.

Additional Sources for CGEM Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle

CGEM Stock Overview

Market Cap in USD 463m
Sector Healthcare
Industry Biotechnology
GiC Sub-Industry Biotechnology
IPO / Inception 2021-01-08

CGEM Stock Ratings

Growth Rating -73.9
Fundamental -60.0
Dividend Rating 0.0
Rel. Strength -48.1
Analysts 4.89 of 5
Fair Price Momentum 5.33 USD
Fair Price DCF -

CGEM Dividends

Currently no dividends paid

CGEM Growth Ratios

Growth Correlation 3m 27.6%
Growth Correlation 12m -93.5%
Growth Correlation 5y -55.4%
CAGR 5y -25.87%
CAGR/Max DD 5y -0.30
Sharpe Ratio 12m -0.44
Alpha -68.11
Beta 0.985
Volatility 56.07%
Current Volume 146.7k
Average Volume 20d 312.1k
What is the price of CGEM shares?
As of July 06, 2025, the stock is trading at USD 7.81 with a total of 146,725 shares traded.
Over the past week, the price has changed by +0.64%, over one month by -13.89%, over three months by +5.40% and over the past year by -51.73%.
Is Cullinan Oncology a good stock to buy?
No, based on ValueRay´s Fundamental Analyses, Cullinan Oncology (NASDAQ:CGEM) is currently (July 2025) a stock to sell. It has a ValueRay Fundamental Rating of -60.00 and therefor a negative outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of CGEM is around 5.33 USD . This means that CGEM is currently overvalued and has a potential downside of -31.75%.
Is CGEM a buy, sell or hold?
Cullinan Oncology has received a consensus analysts rating of 4.89. Therefore, it is recommended to buy CGEM.
  • Strong Buy: 8
  • Buy: 1
  • Hold: 0
  • Sell: 0
  • Strong Sell: 0
What are the forecasts for CGEM share price target?
According to our own proprietary Forecast Model, CGEM Cullinan Oncology will be worth about 6.3 in July 2026. The stock is currently trading at 7.81. This means that the stock has a potential downside of -19.97%.
Issuer Target Up/Down from current
Wallstreet Target Price 26.9 244.2%
Analysts Target Price 26.9 244.2%
ValueRay Target Price 6.3 -20%